Clinical Trials for Multiple Sclerosis

991 multiple sclerosis trials indexed, 428 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Multiple Sclerosis

Multiple sclerosis (MS) is a chronic disease that affects the central nervous system, which includes the brain and spinal cord. It occurs when the immune system mistakenly attacks the protective covering of nerve fibers, called myelin. This damage disrupts communication between the brain and other parts of the body. Doctors diagnose MS based on a combination of medical history, neurological exams, magnetic resonance imaging (MRI), and sometimes analysis of cerebrospinal fluid. These tools help identify areas of inflammation or scarring in the nervous system that are typical of MS.

People with MS can experience a wide range of symptoms depending on the location and severity of nerve damage. Common symptoms include fatigue, numbness or tingling in the limbs, muscle weakness, difficulty walking, vision problems, and problems with coordination or balance. MS usually begins between the ages of 20 and 40 and is more common in women than men. Risk factors include genetic predisposition, environmental factors such as low vitamin D levels, smoking, and certain viral infections. The disease course varies, with some people having periods of relapse and remission, while others experience steady progression.

MS is a significant medical and social concern worldwide. It affects approximately 2.8 million people globally, with an estimated 1 million cases in the United States alone. The disease can lead to physical disability and reduced quality of life, impacting employment and daily activities. Economically, MS places a heavy burden on healthcare systems and families, with annual costs estimated to exceed $30 billion in the U.S. Early diagnosis and management are vital to slowing disease progression and maintaining function.

The Multiple Sclerosis Treatment Landscape

The first-line treatment for MS typically involves disease-modifying therapies (DMTs) aimed at reducing relapse frequency and slowing progression. These therapies include injectable medications such as interferon beta and glatiramer acetate, which have been used for many years. Oral options like dimethyl fumarate and teriflunomide are also common first choices. Treatment usually begins with these safer options, especially for patients with mild to moderate symptoms, and doctors monitor response closely to decide if adjustments are needed.

For patients who do not respond well to first-line treatments or have more aggressive disease, second- and third-line therapies are available. These include monoclonal antibodies such as natalizumab and ocrelizumab, which target specific immune cells involved in MS. Other options include fingolimod, an oral drug that traps immune cells in lymph nodes to prevent them from reaching the brain and spinal cord. These medications generally have stronger effects but may come with increased risks of side effects or infections, so they require careful management.

Despite advances, current treatments do not work equally well for all patients. Some subgroups, such as those with progressive forms of MS, have fewer effective options. Additionally, side effects like flu-like symptoms, liver damage, or increased infection risk can limit the use of some drugs. Resistance to therapy and the need for lifelong treatment also pose challenges. Research is ongoing to find new therapies that target different aspects of the disease, improve safety, and help those with treatment-resistant MS.

Why Clinical Trials Matter for Multiple Sclerosis

Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial can provide closer medical monitoring and contribute valuable information to MS research. Currently, there are 991 multiple sclerosis clinical trials listed on ClinicalTrials.gov, with 428 actively recruiting participants. These studies explore various aspects of MS treatment, including novel drugs, rehabilitation methods, and symptom management strategies. Joining a trial can give patients options beyond standard care, especially if existing treatments are not effective.

It is important to understand the risks involved in clinical trials. New treatments may not work as hoped, and some participants receive placebo instead of active medication. Trials often require more frequent clinic visits and tests, which can be time-consuming. Side effects may also occur, sometimes more severe than those seen with approved therapies. Patients should discuss these factors with their healthcare providers to make informed decisions about joining a trial.

Multiple sclerosis clinical trials are sponsored by a mix of academic institutions, pharmaceutical companies, and cooperative research groups. This diversity helps ensure a wide range of study designs and treatment approaches. ClinicalTrials.gov serves as a comprehensive registry, helping patients and caregivers find trials that match their needs. The site provides detailed information on trial purpose, eligibility, locations, and contact details, making it easier to explore participation opportunities.

What to Look for in a Multiple Sclerosis Clinical Trial

Clinical trials are divided into four main phases, each with a specific purpose. Phase 1 trials focus on safety and dosage, usually involving a small number of participants. Phase 2 trials assess the effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to the current standard in a much larger population. Phase 4 happens after the treatment is approved, monitoring long-term effects. For Multiple Sclerosis trials, the distribution is as follows: 216 trials are not assigned a phase, 118 are in Phase 1, 81 in Phase 2, and 63 in Phase 3. This shows many studies are still early in development.

Inclusion criteria are important to ensure the trial tests the treatment on the right group of patients. For Multiple Sclerosis, common criteria include specific age ranges, often adults between 18 and 65 years old. Trials may require participants to have a confirmed diagnosis of MS with certain types, such as relapsing-remitting or progressive forms. Some trials ask for information about prior treatments, like whether patients have used disease-modifying therapies before. Biomarkers, such as MRI findings or blood tests, may also be part of the criteria. Duration of the disease and current stage can affect eligibility, as some studies focus on early MS while others study later stages.

Exclusion criteria help protect patients and improve the quality of the data. People with other serious health conditions, such as heart disease or uncontrolled diabetes, are often excluded to avoid complications. Drug interactions are a concern, so participants taking medications that could interfere with the trial drug might not be eligible. Safety thresholds, like specific blood pressure or liver function levels, are set to reduce risks. These rules help ensure that only patients who can safely participate and provide clear results are included in the study.

Patients should also consider practical aspects before joining a trial. The length of the trial can vary from a few months to several years. Visit schedules may be frequent, requiring travel to the study site for tests and treatments. This can impact daily life and work. It is helpful to ask the research team questions like: How many visits will I need? What side effects should I expect? Can I continue my current medications? What happens if I want to leave the trial early? Understanding these details helps patients make informed decisions about participation.

Primary Sources and Further Reading

For those interested in learning more about Multiple Sclerosis and clinical trials, reliable sources offer detailed and up-to-date information. These websites provide resources for patients, caregivers, and researchers. They cover symptoms, treatments, ongoing studies, and guidance on how to participate in clinical trials.

Latest Research and Emerging Treatments for Multiple Sclerosis (2026)

Multiple sclerosis research continues to explore new drugs and treatment approaches that may improve patient outcomes. Among recent studies, some trials focus on immune system modulation, which is important because MS involves the immune system attacking nerve cells. For example, trials involving drugs like pasritamig are testing whether redirecting T cells can better control immune responses. Pasritamig is being studied for its ability to guide immune cells to target specific disease processes. While this drug is currently tested in prostate cancer (NCT07164443), similar immune-based strategies are relevant to multiple sclerosis new treatment 2026 efforts.

Other multiple sclerosis treatments under study include hormone-based therapies and targeted antibodies. Although drugs like imlunestrant are primarily tested in breast cancer (NCT05514054), hormone therapies often influence immune function and inflammation, which are key in MS. Early data suggests that modifying hormone signals might help reduce disease activity. Additionally, antibody treatments such as amivantamab, which block specific cell receptors, are being tested in cancer trials (NCT06662786). These antibodies may also have potential in MS by preventing harmful immune cells from damaging nerves.

For patients, these ongoing multiple sclerosis research studies offer hope for more personalized and effective options. New drugs for multiple sclerosis might reduce relapses, slow progression, or improve quality of life by targeting the disease more precisely. While these treatments are still in clinical trials, the growing focus on immune system control and targeted therapies reflects the direction of multiple sclerosis treatment development. Patients and caregivers can follow these trials to learn about emerging options that may become available in the near future.

Frequently asked questions about Multiple Sclerosis trials

How do I find Multiple Sclerosis clinical trials?

The authoritative source for Multiple Sclerosis clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 991 multiple sclerosis studies are currently indexed. You can search by entering "multiple sclerosis" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new multiple sclerosis trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Multiple Sclerosis trials in?

Across the 991 multiple sclerosis trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Multiple Sclerosis clinical trials are currently recruiting?

As of the latest scan, 428 multiple sclerosis trials have a "Recruiting" status on ClinicalTrials.gov, out of 991 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting multiple sclerosis trial matches their tracked condition.

Stay informed about multiple sclerosis research

Get a weekly briefing with the trials that matter most.

Start monitoring multiple sclerosis trials